Assignee
RAQUALIA PHARMA INC
JP·29 granted patents·7 pending applications·87 citations·filing 2006–2022
Top patents by PatentIndex Score
36 records- 0193US9688674B2Selective EP4 receptor antagonistic substance for treatment of cancerRAQUALIA PHARMA INC·Filed 2014·Granted Jun 27, 2017·7 cites·6 claims
- 0290US7479564B2Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agentsRAQUALIA PHARMA INC·Filed 2006·Granted Jan 20, 2009·21 cites·13 claims
- 0389US10093678B2Azaspiro derivatives as TRPM8 antagonistsRAQUALIA PHARMA INC·Filed 2015·Granted Oct 9, 2018·12 cites·17 claims
- 0486US7960407B2Crystal forms of an imidazole derivativeRAQUALIA PHARMA INC·Filed 2006·Granted Jun 14, 2011·15 cites·8 claims
- 0585US9187475B2Pyrrolopyridinone derivatives as TTX-S blockersRAQUALIA PHARMA INC·Filed 2013·Granted Nov 17, 2015·9 cites·10 claims
- 0683US7723321B2Chromane substituted benzimidazole derivativesRAQUALIA PHARMA INC·Filed 2006·Granted May 25, 2010·8 cites·8 claims
- 0780US9522140B2Aryl substituted carboxamide derivatives as calcium or sodium channel blockersRAQUALIA PHARMA INC·Filed 2015·Granted Dec 20, 2016·3 cites·4 claims
- 0880US7718809B2Chromane substituted benzimidazole derivatives as acid pump antagonistsRAQUALIA PHARMA INC·Filed 2006·Granted May 18, 2010·5 cites·5 claims
- 0977US11077100B2Tetrahydroquinoline derivatives as P2X7 receptor antagonistsRAQUALIA PHARMA INC·Filed 2018·Granted Aug 3, 2021·2 cites·41 claims
- 1074US8969383B2Picolinamide derivatives as TTX-S blockersRAQUALIA PHARMA INC·Filed 2014·Granted Mar 3, 2015·2 cites·5 claims
- 1172US12295947B2Tetrahydroquinoline derivatives as P2X7 receptor antagonistsRAQUALIA PHARMA INC·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 1267US9944634B2Pyrazolopyridine derivatives as TTX-S blockersRAQUALIA PHARMA INC·Filed 2013·Granted Apr 17, 2018·1 cites·15 claims
- 1367US9499543B2Polymorph formsRAQUALIA PHARMA INC·Filed 2014·Granted Nov 22, 2016·1 cites·8 claims
- 1466US12552776B2Crystalline formsRAQUALIA PHARMA INC·Filed 2022·Granted Feb 17, 2026·0 cites·13 claims
- 1565US11439633B2Tetrahydroquinoline derivatives as P2X7 receptor antagonistsRAQUALIA PHARMA INC·Filed 2020·Granted Sep 13, 2022·0 cites·2 claims
- 1661US10179779B2Polymorph formsRAQUALIA PHARMA INC·Filed 2013·Granted Jan 15, 2019·1 cites·18 claims
- 1761US2021179613A1Ghrelin receptor agonist for treatment of cachexiaRAQUALIA PHARMA INC·Filed 2021·Application pending·0 cites
- 1855US12521358B2Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agentRAQUALIA PHARMA INC·Filed 2021·Granted Jan 13, 2026·0 cites·14 claims
- 1954US9447065B2Pharmaceutical compositionRAQUALIA PHARMA INC·Filed 2012·Granted Sep 20, 2016·0 cites·18 claims
- 2052US12110287B2Heterocyclic derivatives as Nav1.7 and Nav1.8 blockersRAQUALIA PHARMA INC·Filed 2019·Granted Oct 8, 2024·0 cites·10 claims
- 2152US11135270B2Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)RAQUALIA PHARMA INC·Filed 2018·Granted Oct 5, 2021·0 cites·1 claims
- 2250US2023339934A1Pyrimidin-4(3h)-one derivatives as trpv4 antagonistsRAQUALIA PHARMA INC·Filed 2021·Application pending·0 cites
- 2349US2018339993A1Azaspiro derivatives as trpm8 antagonistsRAQUALIA PHARMA INC·Filed 2018·Application pending·0 cites
- 2449US2023255965A1Trpv4 inhibitor as a therapeutic agent for ocular diseasesRAQUALIA PHARMA INC·Filed 2021·Application pending·0 cites
- 2549US2021379158A1Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (crhr2)RAQUALIA PHARMA INC·Filed 2021·Application pending·0 cites
- 2648US12421191B23-hydroxyoxindole derivatives as CRHR2 antagonistRAQUALIA PHARMA INC·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
- 2748US11020381B2Biaryloxy derivatives as TTX-S blockersRAQUALIA PHARMA INC·Filed 2018·Granted Jun 1, 2021·0 cites·15 claims
- 2843US9701658B2Amide derivatives as TTX-S blockersRAQUALIA PHARMA INC·Filed 2013·Granted Jul 11, 2017·0 cites·12 claims
- 2941US2015099709A1Ghrelin receptor agonists for the treatment of achlorhydriaRAQUALIA PHARMA INC·Filed 2013·Application pending·0 cites
- 3040US11154544B2Amide derivatives as Nav1.7 and Nav1.8 blockersRAQUALIA PHARMA INC·Filed 2018·Granted Oct 26, 2021·0 cites·12 claims
- 3139US11802120B2Fused cyclic urea derivatives as CRHR2 antagonistRAQUALIA PHARMA INC·Filed 2019·Granted Oct 31, 2023·0 cites·15 claims
- 3237US9988370B2Benzisoxazole derivative saltRAQUALIA PHARMA INC·Filed 2015·Granted Jun 5, 2018·0 cites·20 claims
- 3337US9833447B25-HT4 receptor agonist for gastroparesisRAQUALIA PHARMA INC·Filed 2015·Granted Dec 5, 2017·0 cites·6 claims
- 3436US2018305341A1Imidazolinone derivatives as trpm8 antagonistsRAQUALIA PHARMA INC·Filed 2016·Application pending·0 cites
- 3532US9901571B2Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonistsRAQUALIA PHARMA INC·Filed 2015·Granted Feb 27, 2018·0 cites·11 claims
- 3631US9873695B2Serine derivatives as ghrelin receptor agonistsRAQUALIA PHARMA INC·Filed 2015·Granted Jan 23, 2018·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when RAQUALIA PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →